The HTA Review's final report recommended that consideration be given to allowing the PBAC to conditionalise its recommendations. Why? An analysis reveals the committee is already explicitly conditionalising its recommendations, making them effectively provisional.
We don't need new laws for conditional outcomes, because they are already embedded in the system
August 21, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News

